Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
11
Jun
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-06-10 Sumitomo Pharma Co.,Ltd. “Regarding the patient enrollment status of the Phase 2 trial of the investigational anticancer drug enzomenib for acute leukemia.”
06
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-05 Otsuka Holdings Co.,Ltd. “VOYXACT (sibeprenelimab), a treatment for IgA nephropathy, presents favorable eGFR data from a Phase 3 trial – reporting 12 months of maintained renal function at the European Society of Nephrology.”
06
Jun
Otsuka Holdings Co.,Ltd. JP3188220002
2026-06-05 Otsuka Holdings Co.,Ltd. “The National Institute for Environmental Studies and other organizations have established the "Heatstroke Prevention Industry-Government-Academia Collaboration Consortium" to bring together scientific and practical knowledge to reduce the risk of heatstroke caused by climate change.”
06
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-05 Shionogi & Co.,Ltd. “Announcement of the new product launch: "ENDEAVORRIDE®".”
06
Jun
Takeda Pharmaceutical Company Limited JP3463000004
2026-06-05 Takeda Pharmaceutical Company Limited “Regarding the revised financial results for the fiscal year ending March 2026 (FY2025) that reflect the impact of the jury verdict in the antitrust lawsuit concerning AMITIZA®.”
05
Jun
Eisai Co.,Ltd. JP3160400002
2026-06-04 Eisai Co.,Ltd. “Regarding the issuance of unsecured corporate bonds.”
04
Jun
Kyowa Kirin Co.,Ltd. JP3256000005
2026-06-03 Kyowa Kirin Co.,Ltd. “The results of a trial of ziftomenib in combination with venetoclax/azacitidine in patients with NPM1 mutation-induced relapsed/refractory AML have been published in the journal "Blood" (722KB).”
03
Jun
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-06-02 Sumitomo Pharma Co.,Ltd. “Announcement regarding the presentation of clinical data on SMP-3124LP, a novel liposomal CHK1 inhibitor currently under development as an anticancer drug, at the American Society of Clinical Oncology (ASCO) 2026 meeting.”
02
Jun
Shionogi & Co.,Ltd. JP3347200002
2026-06-01 Shionogi & Co.,Ltd. “Regarding the US FDA's approval of the anti-coronavirus (SARS-CoV-2) drug encitrelvir fumarate for post-exposure prevention of COVID-19.”
02
Jun
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-06-01 Sumitomo Pharma Co.,Ltd. “Announcement of organizational changes, changes in the responsibilities of executive officers, and personnel changes.”
02
Jun
Takeda Pharmaceutical Company Limited JP3463000004
2026-06-01 Takeda Pharmaceutical Company Limited “Notice Regarding the Withdrawal of the Issuance Registration and the New Issuance Registration for New Shares.”
30
May
Otsuka Holdings Co.,Ltd. JP3188220002
2026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (ADHD) treatment with a new mechanism of action, was presented at the American Society of Clinical Psychopharmacology (ASCP) annual meeting with post-hoc analysis results from a Phase 3 trial demonstrating improvements in executive function and emotional regulation in adults with ADHD.”
30
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-29 Shionogi & Co.,Ltd. “Regarding the approval of naldemedine, a treatment for opioid-induced constipation, as a new drug in China.”
30
May
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-05-29 Sumitomo Pharma Co.,Ltd. “The "Notice of Convocation of the 206th Ordinary General Meeting of Shareholders" is posted.”
30
May
Astellas Pharma Inc. JP3942400007
2026-05-29 Astellas Pharma Inc. “Notice of resignation of outside director and partial withdrawal of proposals submitted to the 21st Ordinary General Meeting of Shareholders.”
27
May
Eisai Co.,Ltd. JP3160400002
2026-05-26 Eisai Co.,Ltd. “Mitsubishi UFJ Trust and Banking Corporation and Eisai are collaborating to strengthen financial services for the elderly through the provision of information on cognitive function.”
27
May
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-05-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical receives the "Imperial Invention Award," the highest honor at the 2026 National Invention Awards, for its recycling antibody technology, which has been recognized for its contribution to pharmaceutical research.”
27
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-26 Shionogi & Co.,Ltd. “We have posted the "Notice of Convocation of the 161st Ordinary General Meeting of Shareholders."”
27
May
Shionogi & Co.,Ltd. JP3347200002
2026-05-26 Shionogi & Co.,Ltd. “We have posted a notice of partial correction to the Notice of Convocation of the 161st Ordinary General Meeting of Shareholders.”
27
May
Astellas Pharma Inc. JP3942400007
2026-05-26 Astellas Pharma Inc. “Business Plan 2026.”